Assenagon Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14M | Buy |
61,821
+39,610
| +178% | +$7.05M | 0.02% | 476 |
|
|
2026
Q1 | $3.83M | Sell |
22,211
-43,668
| -66% | -$8.1M | 0.01% | 641 |
|
|
2025
Q4 | $13.1M | Buy |
65,879
+33,590
| +104% | +$6.09M | 0.02% | 448 |
|
|
2025
Q3 | $5.05M | Sell |
32,289
-549,216
| -94% | -$87.2M | 0.01% | 616 |
|
|
2025
Q2 | $88.2M | Buy |
581,505
+11,408
| +2% | +$1.52M | 0.13% | 151 |
|
|
2025
Q1 | $85.8M | Buy |
570,097
+538,792
| +1,721% | +$90.3M | 0.14% | 127 |
|
|
2024
Q4 | $5.78M | Sell |
31,305
-17,725
| -36% | -$3.41M | 0.01% | 654 |
|
|
2024
Q3 | $9.66M | Buy |
49,030
+29,621
| +153% | +$6.16M | 0.02% | 544 |
|
|
2024
Q2 | $4.01M | Sell |
19,409
-18,847
| -49% | -$4.27M | 0.01% | 697 |
|
|
2024
Q1 | $10.4M | Buy |
38,256
+12,769
| +50% | +$3.05M | 0.02% | 418 |
|
|
2023
Q4 | $6.03M | Sell |
25,487
-5,604
| -18% | -$1.1M | 0.02% | 581 |
|
|
2023
Q3 | $6.09M | Buy |
+31,091
| New | +$6.38M | 0.02% | 523 |
|
|
2023
Q2 | – | Sell |
-35,017
| Closed | -$7.07M | – | 1354 |
|
|
2023
Q1 | $7.07M | Sell |
35,017
-333
| -0.9% | -$75.5K | 0.03% | 477 |
|
|
2022
Q4 | $7.7M | Sell |
35,350
-25,205
| -42% | -$5.5M | 0.03% | 435 |
|
|
2022
Q3 | $11.9M | Buy |
60,555
+18,561
| +44% | +$4.01M | 0.05% | 312 |
|
|
2022
Q2 | $8.98M | Buy |
41,994
+34,153
| +436% | +$8.35M | 0.03% | 391 |
|
|
2022
Q1 | $2.23M | Sell |
7,841
-12,553
| -62% | -$3.87M | 0.01% | 803 |
|
|
2021
Q4 | $7.68M | Sell |
20,394
-4,197
| -17% | -$1.63M | 0.02% | 398 |
|
|
2021
Q3 | $10.1M | Sell |
24,591
-19,669
| -44% | -$8.17M | 0.03% | 289 |
|
|
2021
Q2 | $16.4M | Sell |
44,260
-44,578
| -50% | -$14.9M | 0.06% | 253 |
|
|
2021
Q1 | $25.7M | Buy |
88,838
+51,144
| +136% | +$14.2M | 0.1% | 169 |
|
|
2020
Q4 | $9.42M | Sell |
37,694
-5,290
| -12% | -$1.26M | 0.04% | 258 |
|
|
2020
Q3 | $9.73M | Buy |
+42,984
| New | +$8.92M | 0.05% | 202 |
|
|
2019
Q3 | – | Sell |
-24,149
| Closed | -$3.43M | – | 880 |
|
|
2019
Q2 | $3.43M | Sell |
24,149
-311,470
| -93% | -$42.2M | 0.03% | 380 |
|
|
2019
Q1 | $48.7M | Buy |
335,619
+262,907
| +362% | +$34.5M | 0.46% | 48 |
|
|
2018
Q4 | $8.23M | Sell |
72,712
-323,739
| -82% | -$40.5M | 0.09% | 171 |
|
|
2018
Q3 | $53.3M | Buy |
396,451
+134,594
| +51% | +$16.6M | 0.53% | 49 |
|
|
2018
Q2 | $29.4M | Buy |
261,857
+130,325
| +99% | +$14.1M | 0.34% | 86 |
|
|
2018
Q1 | $14M | Buy |
+131,532
| New | +$14.2M | 0.18% | 132 |
|
|
2017
Q3 | – | Sell |
-91,221
| Closed | -$9.23M | – | 462 |
|
|
2017
Q2 | $9.23M | Sell |
91,221
-120,821
| -57% | -$11.1M | 0.2% | 61 |
|
|
2017
Q1 | $19.1M | Sell |
212,042
-153,958
| -42% | -$13.1M | 0.41% | 58 |
|
|
2016
Q4 | $27.9M | Buy |
+366,000
| New | +$27.8M | 0.52% | 53 |
|
Other funds holding CRL
AI
Assenagon Asset Management's CRL Position: Q2 2026 in Review
Assenagon Asset Management increased its Charles River Laboratories (CRL) stake by 178% in Q2 2026, buying an estimated $7.05M and bringing the position to 61,821 shares worth $14M. The position accounts for 0.02% of the portfolio, ranked #476.
Assenagon Asset Management first reported a position in CRL in Q4 2016 and has held it in 32 quarters since. The position peaked at $88.2M in Q2 2025. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Assenagon Asset Management held 61,821 shares of Charles River Laboratories worth $14M as of Q2 2026.
- Assenagon Asset Management bought 39,610 Charles River Laboratories shares in Q2 2026, an estimated $7.05M.
- Charles River Laboratories made up 0.02% of Assenagon Asset Management's portfolio in Q2 2026, its #476 holding.
- Assenagon Asset Management first reported a position in Charles River Laboratories in Q4 2016 and has held it in 32 quarters since.
- Assenagon Asset Management's Charles River Laboratories position peaked at $88.2M in Q2 2025.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.